The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Open accessAbstract
BACKGROUND: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. PATIENTS AND METHODS: Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken. RESULTS: Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen. CONCLUSIONS: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Varni, J. W., Burwinkle, T. M., Katz, E. R., Meeske, K., & Dickinson, P. (2002) · Cancer · doi:10.1002/cncr.10428 · Cited by 1,448
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citationSpastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
Barlow, C. F., Priebe, C. J., Mulliken, J. B., Barnes, P. D., Mac Donald, D., Folkman, J., & Ezekowitz, R. A. B. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70034-4 · Cited by 441
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Self-citationBielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Self-citationRosen, G., Murphy, M. L., Huvos, A. G., Gutierrez, M., & Marcove, R. C. (1976) · Cancer · doi:10.1002/1097-0142(197601)37:1<1::aid-cncr2820370102>3.0.co;2-3 · Cited by 353
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Self-citationPlanning the size and duration of a clinical trial studying the time to some critical event
George, S. L., & Desu, M. M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90004-6 · Cited by 279
Synovial sarcoma. Uniform response of metastases to high dose ifosfamide
Rosen, G., Forscher, C., Lowenbraun, S., Eilber, F., Eckardt, J., Holmes, C., & Fu, Y. S. (1994) · Cancer · doi:10.1002/1097-0142(19940515)73:10<2506::aid-cncr2820731009>3.0.co;2-s · Cited by 273
Incidence and survival of malignant bone sarcomas in England 1979–2007
Whelan, J., McTiernan, A., Cooper, N., Wong, Y. K., Francis, M., Vernon, S., & Strauss, S. J. (2012) · International Journal of Cancer · doi:10.1002/ijc.26426 · Cited by 255
Self-citationBacci, G., Picci, P., Ruggieri, P., Mercuri, M., Avella, M., Capanna, R., Brach Del Prever, A., Mancini, A., Gherlinzoni, F., Padovani, G., et al. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m · Cited by 235
Goorin, A. M., Harris, M. B., Bernstein, M. L., Ferguson, W., Devidas, M., Siegal, G. P., Gebhardt, M. C., Schwartz, C. L., Link, M. P., & Grier, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.426 · Cited by 223
Self-citationWhelan, J. S., Jinks, R. C., McTiernan, A., Sydes, M. R., Hook, J. M., Trani, L., Uscinska, B., Bramwell, V., Lewis, I. J., Nooij, M. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr491 · Cited by 205
Self-citationScandinavian Sarcoma Group Osteosarcoma Study SSG VIII
Smeland, S., Müller, C., Alvegard, T. A., Wiklund, T., Wiebe, T., Björk, O., Stenwig, A. E., Willén, H., Holmström, T., Follerås, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00747-5 · Cited by 166
Self-citationLe Deley, M.-C., Guinebretière, J.-M., Gentet, J.-C., Pacquement, H., Pichon, F., Marec-Bérard, P., Entz-Werlé, N., Schmitt, C., Brugières, L., Vanel, D., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.023 · Cited by 162
Bacci, G., Longhi, A., Forni, C., Setola, E., & Ferrari, E. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00546-x · Cited by 155
Quality of life in children and adolescents with cancer
Hinds, P. S. (1990) · Seminars in Oncology Nursing · doi:10.1016/0749-2081(90)90031-y · Cited by 141
Fern, L. A., Lewandowski, J. A., Coxon, K. M., & Whelan, J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70113-5 · Cited by 132
Self-citationInternational Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
Marina, N. M., Bielack, S., Whelan, J. S., Smeland, S., Krailo, M., Sydes, M. R., Butterfaß‐Bahloul, T., Calaminus, G., & Bernstein, M. L. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_18 · Cited by 102
Self-citationFern, L. A., Davies, S., Eden, T. O. B., Feltbower, R. G., Grant, R., Hawkins, M. M., Lewis, I. J., Loucaides, E., Rowntree, C. J., Stenning, S. P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604751 · Cited by 91
Self-citationCalaminus, G., Weinspach, S., Teske, C., et al. (2000) · Klinische Pädiatrie · doi:10.1055/s-2000-9679 · Cited by 88
Self-citationGentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00439-x · Cited by 86 · cited 1×
“[9, 20-22] These important questions were amenable to a relatively simple trial design.”
BackgroundThe role of interferons in the treatment of osteosarcoma
Whelan, J., Patterson, D., Perisoglou, M., Bielack, S., Marina, N. M., Smeland, S., & Bernstein, M. L. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22136 · Cited by 69
Self-citationMcTiernan, A., Jinks, R. C., Sydes, M. R., Uscinska, B., Hook, J., Glabbeke, M. M. V., Bramwell, V. H. C., Lewis, I. J., Taminiau, A. H. M., Nooij, M. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.012 · Cited by 50
Self-citationOsteosarcoma: Time to move on?
Bielack, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.009 · Cited by 20
Self-citationBielack, S., Smeland, S., Whelan, J., Marina, N. M., Hook, J., Jovic, G., Krailo, M., Butterfaß‐Bahloul, T., Kühne, T., Eriksson, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba10504 · Cited by 18
Self-citation
Cited by
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Self-citationSmeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationMarina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Self-citationUpdate on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560
Metadata
- Authors
- Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., Calaminus, G., Capra, M., Deffenbaugh, C., Dhooge, C., Eriksson, M., Flanagan, A. M., Gelderblom, H., Goorin, A., Gorlick, R., Gosheger, G., Grimer, R. J., Hall, K. S., Helmke, K., Hogendoorn, P. C. W., Jundt, G., Kager, L., Kuehne, T., Lau, C. C., Letson, G. D., Meyer, J., Meyers, P. A., Morris, C., Mottl, H., Nadel, H., Nagarajan, R., Randall, R. L., Schomberg, P., Schwarz, R., Teot, L. A., Sydes, M. R., Bernstein, M., Pickering, J., Joffe, N., Kevric, M., Sorg, B., Villaluna, D., Wang, C., Perisoglou, M., Trani, L., Potratz, J., Carrle, D., Wilhelm, M., Zils, K., & Teske, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 26
- Issue
- 2
- Pages
- 407-414
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2118783447
- Cited by
- 333
- References
- 27
- FWCI
- 21.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.